4 Undervalued Pharmaceuticals Stocks for Wednesday, November 06
Discover the top 4 undervalued Pharmaceuticals stocks for Wednesday, November 06 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jack Gilleland
Eunice Kim
Eunice Kim
| Share Statistics | UPC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $24.4 | $586.4 | 11% |
|
| Shares Out (Mil) | 0.6 | 43.1 | 3% |
|
| Institutional Ownership | 1.4% | 83.7% | 2% |
|
| Float (Mil) | 0.6 | 45.1 | 1% |
|
| Beta | 1.59 | 0.73 | 85% |
|
| Avg Daily Volume (000s) | 67 | 331 | 31% |
|
| Price Change (52-week) |
11.7% | 63.2% | 60% |
|
| Growth | UPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.2%) | 6.7% | 5% |
|
| Net Income (5yr) | (20.0%) | (1.4%) | 20% |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | UPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $317 | 12% |
|
| Net Income (TTM) (Mil) | ($2) | ($11) | 36% |
|
| EPS (TTM) | ($3.446) | ($0.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($6) | 19% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $5 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | $2 | $515 | 4% |
|
| Valuation | UPC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.05 | 2.51 | 1% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | UPC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 36.5% | 69.4% | 44% |
|
| Net Margin | (10.9%) | 2.5% | 20% |
|
| ROA | (2.6%) | (22.4%) | 33% |
|
| ROE | (3.5%) | (21.8%) | 32% |
|
| Liabilities to Assets | 22.1% | 32.4% | 15% |
|
| F-Score | 4 | 3 | 33% |
|
Universe Pharmaceuticals INC did not pass any screens on 9/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors